Home Newsfeeds Susquehanna Maintains Neutral on CSX, Raises Price Target to $32

Susquehanna Maintains Neutral on CSX, Raises Price Target to $32

Susquehanna analyst Bascome Majors maintains CSX (NASDAQ:CSX) with a Neutral and raises the price target from $30 to $32.

byBenzinga Newsdesk

January 26, 2023

1 minute read

Susquehanna analyst Bascome Majors maintains CSX (NASDAQ:CSX) with a Neutral and raises the price target from $30 to $32.

Amazon’s Iron Grip: Merchant Suspensions Spark Legal Uproar and Seller Outrage

By Anusuya Lahiri

January 3, 8:49 AM

Amazon.Com Inc's (NASDAQ: AMZN) marketplace is

AMZN

Reported Late Monday, IBM And Rapidus Form Strategic Partnership To Build Advanced Semiconductor Technology And Ecosystem In Japan

By Benzinga Newsdesk

December 13, 1:41 AM

Rapidus, a Newly-Formed Advanced Logic Foundry, Will Leverage IBM's Semiconductor R&D Leadership, Including 2 Nanometer Node Technology TOKYO, Dec. 12, 2022 /PRNewswire/ -- IBM

IBM

Bitcoin At Critical Juncture — Tone Vays Sounds Alarm For Potential ‘Dead Cat Bounce’

By Mehab Qureshi

December 7, 7:40 AM

Tone Vays, a YouTube crypto analyst, has said that Bitcoin (CRYPTO: BTC) is approaching a crucial juncture in its current cycle, which could decide its near-term future.

BTC

FDA Puts Partial Hold On Aeglea’s Rare Disorder Trial In Pediatric Patients

By Vandana Singh

October 4, 11:05 AM

Aeglea BioTherapeutics Inc (NASDAQ:AGLE) received an FDA letter responding to a recently submitted protocol amendment for the Phase 1/2 trial of…

AGLE

Susquehanna Maintains Neutral on CSX, Raises Price Target to $32

Related Posts

Amazon’s Iron Grip: Merchant Suspensions Spark Legal Uproar and Seller Outrage

Reported Late Monday, IBM And Rapidus Form Strategic Partnership To Build Advanced Semiconductor Technology And Ecosystem In Japan

Bitcoin At Critical Juncture — Tone Vays Sounds Alarm For Potential ‘Dead Cat Bounce’

FDA Puts Partial Hold On Aeglea’s Rare Disorder Trial In Pediatric Patients